ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1009

PDE4 Inhibition Could Improve Endothelial and Adipose Tissue Dysfunction Associated with Psoriatic Arthritis, Key Processes in Cardiovascular Disease

Ivan Arias de la Rosa1, Carmen Torres-Granados 1, Maria del Carmen Abalos-Aguilera 2, Ignacio Gomez-Garcia 2, Rocio Guzman-Ruiz 3, Maria del Mar Malagon 3, Carlos Perez-Sanchez 4, Alejandra Patiño-Trives 2, Maria Luque-Tevar 2, Alejandro Ibañez-Costa 2, Alejandro Escudero 5, Eduardo Collantes-Estevez 1, Chary Lopez-Pedrera 2, Maria Dolores Lopez-Montilla 2 and Nuria Barbarroja 3, 1University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, 2IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 3University of Cordoba/IMIBIC/Reina Sofia Hospital and CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain, 4Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, Cordoba, Spain, 5IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: metabolic syndrome and therapeutic targeting, Psoriatic arthritis

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 11, 2019

Session Title: Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Psoriatic arthritis (PsA) is the rheumatic disease most associated with metabolic disorders, including obesity and metabolic syndrome, where inflammation is a determinant key factor, increasing the risk of cardiovascular disease. Thus, searching a therapeutic strategy that could target both inflammation and metabolic complications is of great interest to reduce cardiovascular risk in these patients. Objectives: 1) To analyze the effect of Apremilast in the adipocytokine pattern, metabolic syndrome components and endothelial dysfunction in patients with PsA and metabolic syndrome (MetSyn). 2) To explore the in vitro effects of PDE4 inhibition in the endothelial function and adipocyte biology in the PsA context.

Methods: Methods: human study: twelve PsA patients diagnosed with MetSyn were given apremilast 30 mg twice daily for 6 months. Microvascular endothelial function was measured through post occlusive hyperemia using Laser-Doppler. The levels of cytokines, inflammatory and oxidative stress markers, endothelial adhesion molecules and adipokines were analyzed on serum and peripheral mononuclear blood cells (PMBCs) by ELISA and RT-PCR. Treatment of adipocytes and endothelial cells with serum from PsA patients and apremilast: 3T3L1-differentiated adipocytes and HUVECs were treated with serum 10% of PsA patients and HDs alone or with apremilast (10 mM) for 24h. The expression of adipokines (leptin, adiponectin, visfatin and resistin), adhesion molecules (e-Selectin, VCAM, ICAM), genes involved in inflammation (TNF-a, IL-1b, IL-8 and IL-6), lipid metabolism (DGAT, PLIN, HSL, GLP-1 and PPAR-g), insulin signalling (IRS-1, IRS-2 and GLUT-4) and oxidative stress (SOD-1) was analysed by RT-PCR and western blot.

Results: Results: after 6 months of treatment, Apremilast significantly reduced BMI index, insulin resistance state and levels of complement C3, inflammation, and levels of ApoB. Microvascular endothelial dysfunction was significantly restored shown by an increase of the peak flow and hyperaemia area and decreased adhesion and inflammatory molecules in serum. Altered serum adipokines profile was minimized. mRNA expression levels of inflammatory, adhesion and migration molecules and adipokines were modulated in PMBCs from PsA patients after 6 months with apremilast.

In vitro treatment of endothelial cells with apremilast significantly reduced the expression of adhesion molecules, genes involved in proliferation, adipocytokines and oxidative molecules induced by the serum of PsA patients.

In vitro treatment of adipocytes with apremilast decreased the high levels of leptin, visfatin and resistin induced by PsA serum. In addition, levels of genes involved in lypolisis, adipogenesis and insulin signalling were modulated, favoring an improvement of the insulin resistance induced by PsA serum.  

Conclusion: Conclusions: Our in vivo and in vitro studies suggest that apremilast might reduce IR, inflammation and endothelial dysfunction, parameters strongly involved in cardiovascular disease, by directly targeting adipose tissue and endothelial cells.

Supported by the Minister of Health (ISCIII, PI17/01316, RIER RD16/0012/0015) cofinanced with FEDER funds.


Disclosure: I. Arias de la Rosa, None; C. Torres-Granados, None; M. Abalos-Aguilera, None; I. Gomez-Garcia, None; R. Guzman-Ruiz, None; M. Malagon, None; C. Perez-Sanchez, None; A. Patiño-Trives, None; M. Luque-Tevar, None; A. Ibañez-Costa, None; A. Escudero, None; E. Collantes-Estevez, None; C. Lopez-Pedrera, None; M. Lopez-Montilla, None; N. Barbarroja, None.

To cite this abstract in AMA style:

Arias de la Rosa I, Torres-Granados C, Abalos-Aguilera M, Gomez-Garcia I, Guzman-Ruiz R, Malagon M, Perez-Sanchez C, Patiño-Trives A, Luque-Tevar M, Ibañez-Costa A, Escudero A, Collantes-Estevez E, Lopez-Pedrera C, Lopez-Montilla M, Barbarroja N. PDE4 Inhibition Could Improve Endothelial and Adipose Tissue Dysfunction Associated with Psoriatic Arthritis, Key Processes in Cardiovascular Disease [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/pde4-inhibition-could-improve-endothelial-and-adipose-tissue-dysfunction-associated-with-psoriatic-arthritis-key-processes-in-cardiovascular-disease/. Accessed April 13, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pde4-inhibition-could-improve-endothelial-and-adipose-tissue-dysfunction-associated-with-psoriatic-arthritis-key-processes-in-cardiovascular-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.